Oppenheimer analyst Suraj Kalia reiterated a Perform rating on ResMed (NYSE: RMD).The analyst commented: "F2Q25 revenue rose 10% y/y to ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE